{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:10:52Z","timestamp":1793250652022,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.phrs.2023.106659","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T21:04:16Z","timestamp":1673643856000},"page":"106659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome"],"prefix":"10.1016","volume":"188","author":[{"given":"Konrad","family":"Urbanek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Cappetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Bellocchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Imbrici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialucia","family":"Telesca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Donniacuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Riemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Cianflone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Naviglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Maria","family":"Camerino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Castaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liberato","family":"Berrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Liantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.phrs.2023.106659_bib1","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrneph.2016.113","article-title":"Heart failure and kidney dysfunction: epidemiology, mechanisms and management","volume":"12","author":"Schefold","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.phrs.2023.106659_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104781","article-title":"Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium","volume":"157","author":"Cappetta","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2023.106659_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8912768","article-title":"Dipeptidyl peptidase 4 inhibition ameliorates chronic kidney disease in a model of salt-dependent hypertension","volume":"2019","author":"Cappetta","year":"2019","journal-title":"Oxid. Med. Cell Longev."},{"key":"10.1016\/j.phrs.2023.106659_bib4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3389\/fimmu.2017.00716","article-title":"Involvement of cytokines in the pathogenesis of salt and water imbalance in congestive heart failure","volume":"8","author":"Azzam","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2023.106659_bib5","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.3389\/fphar.2019.01192","article-title":"Inflammation in renal diseases: new and old players","volume":"10","author":"Andrade-Oliveira","year":"2019","journal-title":"Front Pharm."},{"issue":"3","key":"10.1016\/j.phrs.2023.106659_bib6","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/01.HYP.0000056768.03657.B4","article-title":"Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet","volume":"41","author":"Kobori","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2023.106659_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jnutbio.2018.01.007","article-title":"High salt diet induces metabolic alterations in multiple biological processes of Dahl salt-sensitive rats","volume":"56","author":"Wang","year":"2018","journal-title":"J. Nutr. Biochem"},{"issue":"5","key":"10.1016\/j.phrs.2023.106659_bib8","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/HYPERTENSIONAHA.118.11354","article-title":"High salt enhances reactive oxygen species and Angiotensin II contractions of glomerular afferent arterioles from mice with reduced renal mass","volume":"72","author":"Li","year":"2018","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.phrs.2023.106659_bib9","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1152\/physrev.00008.2018","article-title":"Learning physiology from inherited kidney disorders","volume":"99","author":"van der Wijst","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2023.106659_bib10","doi-asserted-by":"crossref","first-page":"14037","DOI":"10.1038\/ncomms14037","article-title":"CD8+ T cells stimulate Na-Cl co-transporter NCC in distal convoluted tubules leading to salt-sensitive hypertension","volume":"8","author":"Liu","year":"2017","journal-title":"Nat. Commun."},{"issue":"13","key":"10.1016\/j.phrs.2023.106659_bib11","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/hmg\/ddm112","article-title":"Common genetic variants and haplotypes in renal CLCNKA gene are associated to salt-sensitive hypertension","volume":"16","author":"Barlassina","year":"2007","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.phrs.2023.106659_bib12","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1073\/pnas.1017494108","article-title":"sequence variant in the CLCNKA chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation","volume":"108","author":"Cappola","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.phrs.2023.106659_bib13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00439-020-02219-2","article-title":"Genetics and phenotypic heterogeneity of Dent disease: the dark side of the moon","volume":"140","author":"Gianesello","year":"2021","journal-title":"Hum. Genet"},{"issue":"4","key":"10.1016\/j.phrs.2023.106659_bib14","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s40620-020-00835-9","article-title":"Downregulation of megalin, cubilin, ClC-5 and podocin in Fabry nephropathy: potential implications in the decreased effectiveness of enzyme replacement therapy","volume":"34","author":"Trimarchi","year":"2021","journal-title":"J. Nephrol."},{"issue":"15","key":"10.1016\/j.phrs.2023.106659_bib15","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"DAPA-CKD trial committees and investigators. Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.phrs.2023.106659_bib16","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"CREDENCE trial investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.phrs.2023.106659_bib17","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"EMPEROR-Reduced trial investigators. cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.phrs.2023.106659_bib18","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"DAPA-HF trial committees and investigators. dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.phrs.2023.106659_bib19","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"CANVAS program collaborative group. canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.phrs.2023.106659_bib20","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1111\/bph.13791","article-title":"Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction","volume":"174","author":"Cappetta","year":"2017","journal-title":"Br. J. Pharm."},{"issue":"3","key":"10.1016\/j.phrs.2023.106659_bib21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/jcsm.12185","article-title":"Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia","volume":"8","author":"Conte","year":"2017","journal-title":"J. Cachex Sarcopenia Muscle"},{"issue":"4","key":"10.1016\/j.phrs.2023.106659_bib22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","article-title":"The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments","volume":"55","author":"Bustin","year":"2009","journal-title":"Clin. Chem."},{"issue":"6","key":"10.1016\/j.phrs.2023.106659_bib23","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/SHK.0b013e3181a5a377","article-title":"Rosiglitazone reduces the inflammatory response in a model of vascular injury in rats","volume":"32","author":"Rinaldi","year":"2009","journal-title":"Shock"},{"issue":"2","key":"10.1016\/j.phrs.2023.106659_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/jhh.2013.55","article-title":"Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage","volume":"28","author":"Mennuni","year":"2014","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.phrs.2023.106659_bib25","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","article-title":"The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease","volume":"99","author":"Remuzzi","year":"2005","journal-title":"Kidney Int Suppl."},{"key":"10.1016\/j.phrs.2023.106659_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.667254","article-title":"The role of Renin-Angiotensin-Aldosterone system in the heart and lung: focus on COVID-19","volume":"12","author":"Mascolo","year":"2021","journal-title":"Front Pharm."},{"issue":"10","key":"10.1016\/j.phrs.2023.106659_bib27","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1016\/j.bbamem.2014.05.017","article-title":"Targeting kidney CLC-K channels: pharmacological profile in a human cell line versus Xenopus oocytes","volume":"1838","author":"Imbrici","year":"2014","journal-title":"Biochim Biophys. Acta"},{"issue":"10258","key":"10.1016\/j.phrs.2023.106659_bib28","first-page":"1204","article-title":"Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD","year":"2019","journal-title":"Lancet"},{"issue":"10075","key":"10.1016\/j.phrs.2023.106659_bib29","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.phrs.2023.106659_bib30","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.pcad.2016.12.003","article-title":"The cardio-renal interrelationship","volume":"59","author":"Boudoulas","year":"2017","journal-title":"Prog. Cardiovasc Dis."},{"key":"10.1016\/j.phrs.2023.106659_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.810791","article-title":"Sodium-glucose cotransporter 2 inhibitors and heart failure: a bedside-to-bench journey","volume":"8","author":"Cappetta","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"10.1016\/j.phrs.2023.106659_bib32","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1111\/dom.13441","article-title":"Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats","volume":"20","author":"Jaikumkao","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2023.106659_bib33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"10.1016\/j.phrs.2023.106659_bib34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1479164117733626","article-title":"Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis","volume":"15","author":"Gaspari","year":"2018","journal-title":"Diab. Vasc. Dis. Res."},{"issue":"5","key":"10.1016\/j.phrs.2023.106659_bib35","doi-asserted-by":"crossref","first-page":"711","DOI":"10.4093\/dmj.2018.0208","article-title":"Effects of Dapagliflozin on endothelial function, renal injury markers, and glycemic control in drug-na\u00efve patients with type 2 diabetes mellitus","volume":"43","author":"Kong","year":"2019","journal-title":"Diabetes Metab. J."},{"issue":"1","key":"10.1016\/j.phrs.2023.106659_bib36","article-title":"Sodium-glucose linked Cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.phrs.2023.106659_bib37","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13228","article-title":"Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease","volume":"5","author":"Ma","year":"2017","journal-title":"Physiol. Rep."},{"issue":"15","key":"10.1016\/j.phrs.2023.106659_bib38","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98720","article-title":"SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy","volume":"3","author":"Cassis","year":"2018","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.phrs.2023.106659_bib39","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","article-title":"A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice","volume":"94","author":"Zhang","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.phrs.2023.106659_bib40","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijcard.2016.04.168","article-title":"Long-term administration of ranolazine attenuates diastolic dysfunction and adverse myocardial remodeling in a model of heart failure with preserved ejection fraction","volume":"217","author":"De Angelis","year":"2016","journal-title":"Int J. Cardiol."},{"issue":"22","key":"10.1016\/j.phrs.2023.106659_bib41","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1111\/bph.13686","article-title":"Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction","volume":"174","author":"Esposito","year":"2017","journal-title":"Br. J. Pharm."},{"issue":"5","key":"10.1016\/j.phrs.2023.106659_bib42","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1161\/01.HYP.0000215579.81408.8e","article-title":"Development of heart failure in chronic hypertensive Dahl rats: focus on heart failure with preserved ejection fraction","volume":"47","author":"Klotz","year":"2006","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.phrs.2023.106659_bib43","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3390\/jcm9082359","article-title":"Endothelial dysfunction in chronic kidney disease, from biology to clinical outcomes: a 2020 update","volume":"9","author":"Roumeliotis","year":"2020","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.phrs.2023.106659_bib44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10741-011-9261-3","article-title":"Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome","volume":"17","author":"Colombo","year":"2012","journal-title":"Heart Fail Rev."},{"issue":"2","key":"10.1016\/j.phrs.2023.106659_bib45","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1161\/HYPERTENSIONAHA.108.112706","article-title":"Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced","volume":"52","author":"Liao","year":"2008","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.phrs.2023.106659_bib46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1161\/HYPERTENSIONAHA.116.07237","article-title":"Activation of human T cells in hypertension: studies of humanized mice and hypertensive humans","volume":"68","author":"Itani","year":"2016","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.phrs.2023.106659_bib47","doi-asserted-by":"crossref","first-page":"F692","DOI":"10.1152\/ajprenal.00053.2022","article-title":"SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na+ transport in Dahl SS rats","volume":"322","author":"Kravtsova","year":"2022","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"4","key":"10.1016\/j.phrs.2023.106659_bib48","first-page":"940","article-title":"The Renin-Angiotensin system in the development of salt-sensitive hypertension in animal models and humans","volume":"3","author":"Rassler","year":"2010","journal-title":"Pharm. (Basel)"},{"issue":"10","key":"10.1016\/j.phrs.2023.106659_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141288","article-title":"Renal effects and underlying molecular mechanisms of long-term salt content diets in spontaneously hypertensive Rats","volume":"10","author":"Berger","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.phrs.2023.106659_bib50","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/HYPERTENSIONAHA.106.076216","article-title":"Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure","volume":"50","author":"Chappell","year":"2007","journal-title":"Hypertension"},{"issue":"16","key":"10.1016\/j.phrs.2023.106659_bib51","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","article-title":"Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure","volume":"136","author":"Packer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2023.106659_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100347","article-title":"Angiotensin II increases activity of the ClC-K2 Cl- channel in collecting duct intercalated cells by stimulating production of reactive oxygen species","volume":"296","author":"Khayyat","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.phrs.2023.106659_bib53","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1089\/ars.2012.5149","article-title":"Reactive oxygen species in inflammation and tissue injury","volume":"20","author":"Mittal","year":"2014","journal-title":"Antioxid. Redox Signal"},{"issue":"7","key":"10.1016\/j.phrs.2023.106659_bib54","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1042\/CS20210094","article-title":"Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice","volume":"135","author":"Miyata","year":"2021","journal-title":"Clin. Sci. (Lond. )"},{"issue":"1","key":"10.1016\/j.phrs.2023.106659_bib55","doi-asserted-by":"crossref","first-page":"F67","DOI":"10.1152\/ajprenal.00402.2019","article-title":"Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells","volume":"318","author":"Satou","year":"2020","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2023.106659_bib56","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12933-021-01252-3","article-title":"Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins","volume":"20","author":"Park","year":"2021","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.phrs.2023.106659_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2019.109506","article-title":"Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition","volume":"68","author":"Das","year":"2020","journal-title":"Cell Signal"},{"issue":"4","key":"10.1016\/j.phrs.2023.106659_bib58","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","article-title":"Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors","volume":"75","author":"Wilcox","year":"2020","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.phrs.2023.106659_bib59","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin","volume":"93","author":"Cherney","year":"2018","journal-title":"Kidney Int."},{"issue":"10","key":"10.1016\/j.phrs.2023.106659_bib60","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.phrs.2023.106659_bib61","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.diabet.2016.12.010","article-title":"Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME","volume":"43","author":"Scheen","year":"2017","journal-title":"Diabetes Metab."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823000154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823000154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:39:35Z","timestamp":1760913575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661823000154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":61,"alternative-id":["S1043661823000154"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106659","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106659","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106659"}}